期刊文献+

降钙素原检测指导慢性阻塞性肺疾病抗生素治疗的价值分析

Application of procalcitonin detection in antibiotic treatment of chronic obstructive pulmonary disease
原文传递
导出
摘要 目的探讨在慢性阻塞性肺疾病患者的抗生素治疗中应用降钙素原检测指导治疗的临床价值。方法筛选出2018年5月至2019年5月于河南科技大学第三附属医院慢性阻塞性肺疾病患者100例,应用数字随机表将患者分为对照组与观察组,每组50例。对照组运用基础性的诊治方案,观察组运用降钙素原检测方式指导治疗。比较两组的临床诊治有效性、抗生素使用率、抗生素用药时间、抗生素用药费用、在院诊治时长、住院治疗费用。结果接受治疗后,两组的临床诊治有效性对照,差异未见统计学意义(P> 0.05)。较之对照组,观察组在抗生素使用率、抗生素用药时间、抗生素用药费用、在院诊治时长、住院治疗费用等方面更优(P <0.05)。结论在慢性阻塞性肺疾病患者的抗生素治疗中加入降钙素原检测方式指导治疗,诊治结局甚佳,能够有效缩减患者的抗生素用药时间及在院诊治时间,对抗生素使用率的降低具有积极意义,有助于患者获得良好预后。 Objective To investigate the clinical application value of adding procalcitonin detection method in the treatment of antibiotics in patients with chronic obstructive pulmonary disease( COPD). Methods A total of 100 patients with chronic obstructive pulmonary disease treated in the Third Affiliated Hospital of Henan University of Science and Technology from May 2018 to May 2019 were selected. The patients were divided into control group and observation group by digital random table,with50 cases in each group. The control group used a basic diagnosis and treatment plan,and the observation group used procalcitonin detection to guide treatment. The effectiveness of clinical diagnosis and treatment,antibiotic use rate,antibiotic medication time,antibiotic medication cost,hospital treatment duration,and hospitalization cost were compared. Results After treatment,there was no significant difference in the clinical effective rate of diagnosis and treatment between the two groups( P > 0. 05).Compared with the control group,the observation group was better in the use rate of antibiotics,the duration of antibiotic use,the cost of antibiotics,the length of time in hospital diagnosis and treatment,hospitalization costs and so on( P < 0. 05). Conclusions Adding procalcitonin test in the antibiotic treatment of patients with COPD can effectively reduce the antibiotic use time and hospital diagnosis and treatment time,and has positive significance in the reduction of antibiotic use rate,which helps patients to obtain good prognosis.
作者 王悦轩 李晓琳 吉瑜虹 Wang Yuexuan;Li Xiaolin;Ji Yuhong(Department of Respiratory Medicine,the Third Affiliated Hospital of Henan University of Science and Technology(Luoyang Dongfang Hospital),Luoyang 471003,China)
出处 《临床医学》 CAS 2020年第11期24-26,共3页 Clinical Medicine
关键词 降钙素原 慢性阻塞性肺疾病 抗生素 应用价值 Procalcitonin Chronic obstructive pulmonary disease Antibiotics Application value
  • 相关文献

参考文献6

二级参考文献69

  • 1常春,姚婉贞,陈亚红,刘振英,张晓伟.慢性阻塞性肺疾病患者急性加重期血清降钙素原水平的变化及临床意义[J].中华结核和呼吸杂志,2006,29(7):444-447. 被引量:93
  • 2Brusasco V,Martinez F.Chronic obstructive pulmonary disease[J].Compr Physiol,2014,4(1):1-31. 被引量:1
  • 3Rosenberg SR,Kalhan R.Biomarkers in chronic obstructive pulmonary disease[J].Transl Res,2012,159(4):228-237. 被引量:1
  • 4Assiscot M,Gendrel D,Carsin H,et al.High Serum procalcitonnin concentrations in patients with sepsis and infect[J].Lancet,1993,341(8844):515-518. 被引量:1
  • 5Levy MM,Fink MP,Marshal JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference[J].Intensive Care Med,2003,31(4):1250-1256. 被引量:1
  • 6Schuetz P,Albrich W,Mueller B.Procalcitonin for diagnosis of infection and guide to antibiotic decisions:past,present and future[J].BMC Med,2011,9:107. 被引量:1
  • 7Rammaert B,Verdier N,Cavestri B,et al.Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease[J].Respirology,2009,14(7):969-974. 被引量:1
  • 8Lee H.Procalcitonin as a biomarker of infectious diseases[J].Korean J Intern Med,2013,28(3):285-291. 被引量:1
  • 9Foushee JA,Hope NH,Grace EE.Applying biomarkers to clinical practice:a guide for utilizing procalcitonin assays[J].J Antimicrob Chemother,2012,67(11):2560-2569. 被引量:1
  • 10Irwin AD,Carrol ED.Procalcitonin[J].Arch Dis Child Educ Pract Ed,2011,96(6):228-233. 被引量:1

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部